In the TCGA cohort, glioma patients of the cluster 1 subgroup with the clinicopathological characteristics, age > 45 years, more malignant type of histology, higher WHO grade, IDH wild type, 1p19q codeletion non-codel, and MGMT promoter unmethylated showed significantly higher levels of risk score, while no differences were observed between patients satisfied by gender (Fig. 4B–I). Here, MGMT is linked to central nervous system cancer.